Ignite Creation Date:
2024-05-06 @ 3:12 PM
Last Modification Date:
2024-10-26 @ 1:45 PM
Study NCT ID:
NCT04555148
Status:
COMPLETED
Last Update Posted:
2021-08-24
First Post:
2020-09-16
Brief Title:
COVIDIG COVID-19 Hyper-ImmunoGlobulin
Sponsor:
Green Cross Corporation
Organization:
GC Biopharma Corp
Study Overview
Official Title:
A Prospective Open-label Randomized Multi-center Phase 2a Study to Evaluation the Dose Response Efficacy and Safety of Hyper-Ig Hyper-immunoglobulin GC5131 in Patients With COVID-19
Status:
COMPLETED
Status Verified Date:
2021-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this study is to evaluate the efficacy and safety of 5131A for hospitalized patients of COVID-19
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None